SIX P-A FIRMS WILL SPONSOR PHARMACY STUDENT INTERNS THIS SUMMER, PERGOLA SAYS
Six P-A member firms will be sponsoring internships for pharmacy students this summer based on a program initiated by Norcliff Thayer last year, company President and P-A Chairman Charles Pergola said May 16 in his address to the annual meeting. Pergola will again head the assn. in 1984 after being re-elected during the meeting for a second term. Pergola said that last year Norcliff Thayer employed two University of Connecticut pharmacy school students for an 11-week training program. The firm produced a training manual which was subsequently reproduced by the P-A staff and mailed to all active assn. members. In addition to the six companies who will sponsor interns this summer, Pergola said, "a number of other companies have indicated interest in conducting similar programs at a later date." He added: "I'd like to see at least 12 more member companies join up and participate in this program." Pergola, a pharmacist himself, noted that when he became P-A chairman last year, one of his top priorities was to improve the assn.'s relations with professional pharmacy. The intern program has the support of the American Assn. of Colleges of Pharmacy, Pergola said, adding that he will speak to the group's Council of Deans annual meeting in July. The assn. added three first-time board members during its annual meeting. They are: Thompson Medical Chairman Daniel Abraham (three years); Bristol-Myers Exec-VP Bruce Gelb (two years); and Schmid Labs President Willard Moran (two years). P-A also elected two new VPs for 1984. They are Johnson & Johnson Exec Comte. Member David Collins, and Burroughs Wellcome Chairman and President William Sullivan.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth